ZFGN - ザフゲン （Zafgen Inc.）ZFGNのニュース
Zafgen (NASDAQ:ZFGN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS 2019/11/07 22:46:44 Modern Readers
Zafgen (NASDAQ:ZFGN) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03, Fidelity Earnings reports. NASDAQ ZFGN traded up $0.02 during mid-day trading on Thursday, reaching $0.76. 457,450 shares of the company’s stock traded hands, compared to its average volume of 359,394. […]
The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication 2019/09/06 11:27:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure Inc (NASDAQ: NXTC ) Pfenex Inc (NYSE: PFNX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 5) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) BioNano Genomics Inc (NASDAQ: BNGO ) Endologix, Inc. (NASDAQ: ELGX ) Mallinckrodt PLC (NYSE: MNK ) ( retreated amid reports of restructuring ahead of Cleveland opioid litigation) Merit Medical Systems, Inc. (NASDAQ: MMSI ) VBI Vaccines Inc (NASDAQ: VBIV ) Zafgen Inc (NASDAQ: ZFGN ) ( announced decision to explore strategic options) See Also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Neon's Process To Predict Neoantigens To Control Tumor Growth Published In Scientific Journal Neon Therapeutics Inc (NASDAQ: NTGN ) announced publication in the scientific journal "Immunity," a breakthrough process for predicting which neoantigens will be presented by MHC Class II molecules in the tumor microenvironment.
Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes Drug 2019/09/05 15:24:19 Benzinga
Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics and into the commercialization stage. Earlier this week, Abeona Therapeutics Inc (NASDAQ: ABEO ) opted to explore strategic options, and another biotech has now made a similar announcement. What Happened Zafgen Inc (NASDAQ: ZFGN ), a micro-cap biopharma, announced Thursday that it plans to explore strategic options to maximize shareholder value. The strategic alternatives being evaluated include an acquisition, merger, business combination, in-licensing or other strategic transaction involving the company and its … Full story available on Benzinga.com
The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO 2019/08/27 11:29:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 26) Advaxis, Inc. (NASDAQ: ADXS ) Arbutus Biopharma Corp (NASDAQ: ABUS ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Avanos Medical Inc (NYSE: AVNS ) Cancer Genetics Inc (NASDAQ: CGIX ) Clearside Biomedical Inc (NASDAQ: CLSD ) Elanco Animal Health Inc (NYSE: ELAN )(Bank of America downgraded the shares to Neutral) Neurometrix Inc (NASDAQ: NURO ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tocagen Inc (NASDAQ: TOCA ) Unity Biotechnology Inc (NASDAQ: UBX ) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Nuvectra To Explore Strategic Options Nuvectra Corp (NASDAQ: NVTR ) announced its decision to explore strategic alternatives to …
How Many Zafgen, Inc. (NASDAQ:ZFGN) Shares Do Institutions Own? 2019/07/18 17:17:45 Yahoo Finance
The big shareholder groups in Zafgen, Inc. (NASDAQ:ZFGN) have power over the company. Insiders often own a large chunk…
Zafgen (NASDAQ:ZFGN) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS 2019/11/07 22:46:44 Modern Readers
Zafgen (NASDAQ:ZFGN) announced its earnings results on Wednesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.03, Fidelity Earnings reports. NASDAQ ZFGN traded up $0.02 during mid-day trading on Thursday, reaching $0.76. 457,450 shares of the company’s stock traded hands, compared to its average volume of 359,394. […]
The Daily Biotech Pulse: European Nod For Roche, Takeda Recall, Neon Exults On Journal Publication 2019/09/06 11:27:25 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Sept. 5) Bioanalytical Systems, Inc. (NASDAQ: BASI ) NextCure Inc (NASDAQ: NXTC ) Pfenex Inc (NYSE: PFNX ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) ResMed Inc. (NYSE: RMD ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Sept. 5) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) BioNano Genomics Inc (NASDAQ: BNGO ) Endologix, Inc. (NASDAQ: ELGX ) Mallinckrodt PLC (NYSE: MNK ) ( retreated amid reports of restructuring ahead of Cleveland opioid litigation) Merit Medical Systems, Inc. (NASDAQ: MMSI ) VBI Vaccines Inc (NASDAQ: VBIV ) Zafgen Inc (NASDAQ: ZFGN ) ( announced decision to explore strategic options) See Also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Stocks In Focus Neon's Process To Predict Neoantigens To Control Tumor Growth Published In Scientific Journal Neon Therapeutics Inc (NASDAQ: NTGN ) announced publication in the scientific journal "Immunity," a breakthrough process for predicting which neoantigens will be presented by MHC Class II molecules in the tumor microenvironment.
Zafgen To Explore Strategic Options, With No Near-Term Resolution For Diabetes Drug 2019/09/05 15:24:19 Benzinga
Clinical-stage biopharma companies often face the risk of running out of cash reserves to fund their operations until they can push their investigational assets out of the clinics and into the commercialization stage. Earlier this week, Abeona Therapeutics Inc (NASDAQ: ABEO ) opted to explore strategic options, and another biotech has now made a similar announcement. What Happened Zafgen Inc (NASDAQ: ZFGN ), a micro-cap biopharma, announced Thursday that it plans to explore strategic options to maximize shareholder value. The strategic alternatives being evaluated include an acquisition, merger, business combination, in-licensing or other strategic transaction involving the company and its … Full story available on Benzinga.com
The Daily Biotech Pulse: Nuvectra Explores Strategic Options, J&J To Contend Opioid Ruling, Sesen Bio Gets New CFO 2019/08/27 11:29:00 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 26) DURECT Corporation (NASDAQ: DRRX ) Stoke Therapeutics Inc (NASDAQ: STOK ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 26) Advaxis, Inc. (NASDAQ: ADXS ) Arbutus Biopharma Corp (NASDAQ: ABUS ) ASLAN PHARMACEU/ADR (NASDAQ: ASLN ) Avanos Medical Inc (NYSE: AVNS ) Cancer Genetics Inc (NASDAQ: CGIX ) Clearside Biomedical Inc (NASDAQ: CLSD ) Elanco Animal Health Inc (NYSE: ELAN )(Bank of America downgraded the shares to Neutral) Neurometrix Inc (NASDAQ: NURO ) Regeneron Pharmaceuticals Inc (NASDAQ: REGN ) Stealth BioTherapeutics Corp (NASDAQ: MITO ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Tocagen Inc (NASDAQ: TOCA ) Unity Biotechnology Inc (NASDAQ: UBX ) Zafgen Inc (NASDAQ: ZFGN ) Stocks In Focus Nuvectra To Explore Strategic Options Nuvectra Corp (NASDAQ: NVTR ) announced its decision to explore strategic alternatives to …